Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of liposomal paclitaxel + carboplatin + PD-1 antibody in first-line treatment of advanced lung squamous cell carcinoma
ChiCTR2100050475Phase 4Recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Aug 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of liposomal paclitaxel, carboplatin and PD-1 Monoclonal Antibody in Pulmonary squamous cell carcinoma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Progression-free survival. Started Aug 2021; status: recruiting.
02
Drugs
liposomal paclitaxelcarboplatinPD-1 Monoclonal Antibody
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on ChiCTR2100050475.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050475.